EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische StudieOpen Access · CC BY 4.0

Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real‐world settings: Insights from REVEAL ‐ CKD

Navdeep Tangri iD, Christian S Alvarez, Matthew Arnold, Salvatore Barone, Ana Cebrián, Hungta Chen, Luca De Nicola, Krister Järbrink, Naresh Kanumilli, Kean-Seng Lim, Toshiki Moriyama, Roberto Pecoits Filho und 5 weitere

European Journal of Clinical Investigation · 2024

DOI: 10.1111/eci.14282 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift European Journal of Clinical Investigation, 2024. Verfasst von Navdeep Tangri und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada. Hauptthemen laut MEDLINE: Glomerular Filtration Rate, Renal Insufficiency, Chronic. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Clinical practice guidelines for patients with chronic kidney disease (CKD) recommend regular monitoring and management of kidney function and CKD risk factors. However, the majority of patients with stage 3 CKD lack a diagnosis code, and data on the implementation of these recommendations in the real world are limited.

Aim

To assess the implementation of guideline‐directed monitoring and management practices in the real world in patients with stage 3 CKD without a recorded diagnosis code.

Methods

REVEAL‐CKD (NCT04847531) is a multinational, observational study of patients with stage 3 CKD. Eligible patients had ≥2 consecutive estimated glomerular filtration rate (eGFR) measurements indicative of stage 3 CKD recorded >90 and ≤730 days apart, lacked an International Classification of Diseases 9/10 diagnosis code corresponding to CKD any time before and up to 6 months after the second eGFR measurement. Testing of key measures of care quality were assessed.

Results

The study included 435,971 patients from 9 countries. In all countries, the prevalence of urinary albumin–creatinine ratio and albuminuria testing was low. Angiotensin‐converting enzyme inhibitor, angiotensin receptor blocker and statin prescriptions were highly variable, and sodium–glucose cotransporter‐2 inhibitor prescriptions remained below 21%. Blood pressure measurements were recorded in 20.2%–89.9% of patients.

Conclusions

Overall, a large proportion of patients with evidence of stage 3 CKD did not receive recommended, guideline‐directed monitoring and management. The variability in standard of care among countries demonstrates a clear opportunity to improve monitoring and management of these patients, most likely improving long‐term outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Glomerular Filtration RateRenal Insufficiency, ChronicHumansMaleFemaleAgedMiddle AgedAngiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsAlbuminuriaHydroxymethylglutaryl-CoA Reductase InhibitorsGuideline AdherenceSodium-Glucose Transporter 2 InhibitorsCreatinineBlood PressurePractice Guidelines as Topic

Stichwörter der Autor:innen

chronic kidney diseaseclinical guidelinesmanagementmonitoringreal‐world

Substanzen

Angiotensin-Converting Enzyme InhibitorsAngiotensin Receptor AntagonistsHydroxymethylglutaryl-CoA Reductase InhibitorsSodium-Glucose Transporter 2 InhibitorsCreatinine

Autor:innen und Institutionen

  • Department of Internal Medicine, University of Manitoba, Winnipeg, Manitoba, Canada.
  • Cardiovascular, Renal and Metabolism Epidemiology, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
  • Real World Evidence Data & Analytics, BioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
  • Global Medical Affairs, BioPharmaceuticals Medical, AstraZeneca, Gaithersburg, Maryland, USA.
  • Primary Care Center Cartagena Casco, Cartagena, Murcia, Spain.
  • Biomedical Research Institute of Murcia (IMIB), Murcia, Spain.

ORCID-Profile: Navdeep Tangri

Zitieren

APA

Tangri, N., Alvarez, C. S., Arnold, M., Barone, S., Cebrián, A., Chen, H., De Nicola, L., Järbrink, K., Kanumilli, N., Lim, K. S., Moriyama, T., Pecoits Filho, R., Ribeiro de Castro, M. C., Santamaria, R., Schneider, M. P., Virgitti, J. B., & Kushner, P. (2024). Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real‐world settings: Insights from REVEAL ‐ CKD. European Journal of Clinical Investigation. https://doi.org/10.1111/eci.14282

Vancouver

Tangri N, Alvarez CS, Arnold M, Barone S, Cebrián A, Chen H, et al. Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real‐world settings: Insights from REVEAL ‐ CKD. European Journal of Clinical Investigation. 2024. doi:10.1111/eci.14282

BibTeX
@article{Tangri2024,
  author = {Tangri, Navdeep and Alvarez, Christian S and Arnold, Matthew and Barone, Salvatore and Cebrián, Ana and Chen, Hungta and De Nicola, Luca and Järbrink, Krister and Kanumilli, Naresh and Lim, Kean-Seng and Moriyama, Toshiki and Pecoits Filho, Roberto and Ribeiro de Castro, Maria Cristina and Santamaria, Rafael and Schneider, Markus P and Virgitti, Jean Blaise and Kushner, Pamela},
  title = {Suboptimal monitoring and management in patients with unrecorded stage 3 chronic kidney disease in real‐world settings: Insights from REVEAL ‐ CKD},
  journal = {European Journal of Clinical Investigation},
  year = {2024},
  doi = {10.1111/eci.14282}
}
Kostenlos starten →